CURX

CURANEX PHARMACEUTICALS INC

• Benzinga·3d ago

  EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives

• Benzinga·3d ago

  12 Health Care Stocks Moving In Tuesday's Pre-Market Session

• NASDAQ·4d ago

  Curanex Showcases Patient Case Study Highlighting Potential Of Phyto-N; Stock Up

• TipRanks·4d ago

  Curanex highlights patient case study in treatment of cancer cachexia

• Reuters·4d ago

  Curanex highlights Phyto-N case study supporting potential cancer cachexia supportive-care use

• Benzinga·4d ago

  EXCLUSIVE: Curanex Highlights Case Study Supporting Cachexia Focus In Oncology Strategy

• TipRanks·04/02 13:20

  Curanex Adds Cancer Cachexia to Core Drug Pipeline

• Reuters·04/02 12:22

  CURANEX PHARMACEUTICALS INC - TO FOCUS ON CANCER CACHEXIA AS NEW CORE INDICATION - SEC FILING

• Reuters·04/02 12:08

  Curanex targets cancer cachexia in pipeline expansion to broaden therapeutics focus

• Benzinga·04/02 11:53

  EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases

• Reuters·03/19 00:43

  Curanex Phyto-N repeat-dose study shows no toxicology findings at maximum feasible dose

• TipRanks·03/18 12:17

  Curanex completes dose-range finding toxicology study of Phyto-N

• Benzinga·03/18 12:05

  Curanex Pharmaceuticals Completes Dose-Range Finding Toxicology Study Of Phyto-N; No Findings Of Toxicological Significance At Maximum Feasible Dose

• Reuters·03/18 12:05

  Curanex reports no toxicology findings at maximum feasible dose in 28-day Phyto-N study

• Reuters·03/18 12:04

  CURANEX PHARMACEUTICALS INC - TARGETS IND SUBMISSION FOR PHYTO-N IN Q4 2026